In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Set Alert for Articles By Mike Ward

Latest From Mike Ward

Molecule Diversity Creates Developmental Challenges For Aspiring Commercial Biotechs

Speaking on the sidelines at BIO-Europe 2018, Jenifer Wheat, head of commercial development at Lonza’s mammalian and microbial MMBU, explains to Scrip how having a manufacturing component in their commercialization strategies can facilitate success. Even those companies not planning to launch their own products but planning to license programs to partners can benefit from support from the contract development manufacturing sector.

Strategy Manufacturing

Biotech Showcase 2019: Stem Cell Approach Shows Promise In Neurodegeneration

Recent studies have shown that mesenchymal stem cells (MSCs) hold great potential as a cell‐based therapy for a number of neurodegenerative diseases. Speaking on the sidelines of Biotech Showcase 2019, Chaim Lebovitz, President and CEO of Brainstorm Cell Therapeutics, tells Scrip how the New York-based biotech is currently enrolling a multi-dose, double-blind, placebo-controlled Phase III study of its MSC therapy, leveraging the company’s NurOwn platform, in 200 rapid-progressing amyotrophic lateral sclerosis patients.

Clinical Trials Regenerative Medicine

Biotech Showcase 2019: Harnessing IgE Antibodies To Tackle Solid Cancers

Immuno-oncology is currently one of the hottest spaces for biotechs and so to rise above the noise companies need to be truly differentiated. Speaking on the sidelines of Biotech Showcase 2019, Tim Wilson, CEO of Cambridge, UK-based IGEM Therapeutics, tells Scrip how his company is achieving this by developing IgE antibody drugs to fight cancer, with its lead program against ovarian cancer already in Phase I testing.

ImmunoOncology Innovation

Biotech Showcase 2019: Takeda Establishes Digital Health Focused Fund

Digital health represents a set of opportunities that can transform all parts of the pharma landscape. Speaking on the sidelines of Biotech Showcase 2019, Stephanie Bova, managing partner at Hatch@Takeda, tells Scrip how the Japanese pharma has established a new group to support the creation and financing of digital health businesses in the US and Europe.

Financing Digital Health

Video: Novo Seeds Describes Company-Building Aspirations

With a focus on innovative early stage European biotechs, Novo Seeds senior partner Stephan Christgau explains to Scrip how the investor picks opportunities and creates companies.

Financing Companies

J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts

Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: US generics see gains, researcher calls for more tech transfer, and biotech investor sentiment rises as big deals bring optimism – among other items from the last day of this year's JPM. 

Business Strategies Regenerative Medicine
See All